5C6 Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€8.76M
Enterprise Value€9.07M
Total Cash (Recent Filing)€990.00K
Total Debt (Recent Filing)€1.46M
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding6,443,731,400
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.91
Price to Sales (P/S)0.66
P/FCF Ratio-2.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And StabilizationStabilized revenue and a 33.9% rebound in 2025 indicate improving market traction and demand for core offerings. Over the next several quarters this foundation can enable scalable top-line growth, improve operating leverage potential, and reduce short-term revenue volatility if sustained.
Manageable Leverage In Latest YearRelatively low absolute debt vs equity in 2025 implies manageable leverage and greater financial flexibility versus highly indebted peers. This provides runway to execute operational adjustments or fund near-term needs without immediate solvency pressure, supporting strategic options over coming months.
Positive Gross Profit BaseA positive gross profit means core diagnostics/services produce margin before overhead. That demonstrates viable unit economics; with disciplined cost control or revenue scale, the company has a clear pathway to convert gross profits into operating profit over several quarters, improving structural profitability.
Bears Say
Persistent Negative Operating And Free Cash FlowMulti-year negative operating and free cash flow signal persistent cash burn that raises funding and dilution risk. Over a 2–6 month horizon this constrains investment in R&D, commercial expansion, or working capital, and makes the company reliant on external financing unless cash generation reverses.
Widening Net LossesA large jump in net losses despite revenue rebound indicates operating cost structure or one-off charges are overwhelming income. Continued widening losses erode shareholder value, increase capital needs, and complicate achieving sustainable profitability without substantive structural changes.
Erosion Of Equity And Negative ROEDeclining equity and persistent negative ROE reduce the company’s capital buffer and financial resilience. This structural deterioration limits borrowing capacity, raises refinancing risk, and increases the likelihood of dilutive capital raises if losses persist, undermining long-term shareholder value.
Clearbridge Health Ltd. News
5C6 FAQ
What was Clearbridge Health Ltd.’s price range in the past 12 months?
Clearbridge Health Ltd. lowest stock price was €0.01 and its highest was €0.03 in the past 12 months.
What is Clearbridge Health Ltd.’s market cap?
Clearbridge Health Ltd.’s market cap is €8.76M.
When is Clearbridge Health Ltd.’s upcoming earnings report date?
Clearbridge Health Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 23 days.
How were Clearbridge Health Ltd.’s earnings last quarter?
Clearbridge Health Ltd. released its earnings results on Feb 27, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.
Is Clearbridge Health Ltd. overvalued?
According to Wall Street analysts Clearbridge Health Ltd.’s price is currently Overvalued.
Does Clearbridge Health Ltd. pay dividends?
Clearbridge Health Ltd. does not currently pay dividends.
What is Clearbridge Health Ltd.’s EPS estimate?
Clearbridge Health Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clearbridge Health Ltd. have?
Clearbridge Health Ltd. has 6,443,731,400 shares outstanding.
What happened to Clearbridge Health Ltd.’s price movement after its last earnings report?
Clearbridge Health Ltd. reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Clearbridge Health Ltd.?
Currently, no hedge funds are holding shares in DE:5C6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clearbridge Health Ltd.
Established in 2010 and headquartered in Singapore, Clearbridge Health Limited operates as an investment holding company, delivering diverse healthcare solutions globally, including in Singapore, the Philippines, Hong Kong, and Malaysia. The firm's activities are organized into three key divisions: Strategic Investments, Healthcare Systems, and Medical Clinics/Centres. Its extensive range of services encompasses advanced imaging diagnostics, such as general X-ray, CT scans (including dental cone beam), mammography, MRI, and ultrasound. Furthermore, Clearbridge offers general wellness screenings for conditions like diabetes, high blood pressure, and elevated cholesterol, alongside vaccination programs. Specialized care includes renal treatment, clinical services, aesthetic procedures, and dental and orthodontic services. Beyond patient care, the company provides consultancy to healthcare organizations and is involved in the wholesale supply of medicinal and pharmaceutical products.
Asiamedic Limited
―
AJJ Medtech Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―
Quantum Healthcare Ltd.
―